Medtronic to invest in six new clinical trials

By Lisa Kerner

Erie, Pa., April 24 - Medtronic, Inc. said that during its next fiscal year beginning May 1 the company will invest an unspecified amount in at least six new major clinical trials to determine class 1 evidence of therapies that use its neuromodulation or radio-frequency technology.

The trials will target the treatment of Parkinson's disease, depression, chronic pain, severe spasticity, overactive bladder and benign prostatic hyperplasia.

Ongoing trials of separate treatments for obesity and epilepsy will continue.

"Clinical trials that establish class I evidence pave the way for most treatments that are recognized as standards of care," neurological and urological therapies division president Richard E. Kuntz said in a company news release.

Medtronic is a pharmaceutical company located in Minneapolis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.